Fabry disease
About
Fabry disease is caused by mutations in the GLA gene that lead to a deficiency of alpha-galactosidase A, and glucosaccharide ceramide accumulates in the vascular endothelium and various tissues. It is an X-linked lysosomal storage disorder. Core dilemmas: ① Enzyme replacement therapy requires lifelong intravenous infusion;②ERT has limited effect on cardiac lesions;③ Some patients produce antibodies that affect efficacy;④ Cardiovascular, renal and cerebrovascular complications are the main cause of death.
Features & Symptoms
- GLA gene mutation
- α-galactosidase A deficiency
- Limb pain, hyposweating
- Cardiovascular, renal and cerebrovascular disease
Treatment Options
| Treatment | Description | Stage | Price Range |
|---|---|---|---|
| Agalsidase alfa/beta | Recombinant alpha-galactosidase A, given intravenously every 2 weeks, is the standard enzyme replacement treatment for Fabry disease. | FDA批准 | $200K - $400K/年 |
| Migalastat | Pharmacological companion, administered orally, indicated for patients with specific mutable types. | FDA批准 | $300K - $600K/年 |
| gene therapy | AAV vectors deliver normal GLA genes and are currently in clinical trials. | Phase I/II | $500K - $1.5M/次（一次性） |
Prognosis
ERT delays progression, and the average life expectancy of male patients is approximately 50-60 years old
Additional Notes
Notes: Multidisciplinary Management: Need collaboration from cardiology (cardiomyopathy and valvular disease), nephrology (proteinuria and renal function), and neurology (stroke and pain); Timing of ERT activation: It is recommended to initiate ERT as soon as possible before irreversible organ damage occurs; Antibody monitoring: Some patients develop anti-ERT antibodies, and antibody titers need to be monitored regularly; Pain management: Gabapentin or pregabalin can be used for neuropathic pain; Stroke prevention: Increased risk of white matter disease and stroke, regular brain MRI examination is recommended and cardiovascular risk factors are recommended.; Exclusive service commitment: The platform will allocate a dedicated medical team to each patient to assist in dismantling and properly deploying the following precautions throughout the process. When cross-state and cross-border diagnosis and treatment projects or drugs are involved, the platform will make overall arrangements for the entire docking; for disabled and semi-disabled patient groups, the platform will provide rush-free alternative solutions (including remote consultation, door-to-door sampling, direct drug delivery in the cold chain, etc.), to ensure that patients can get the same high-quality diagnosis and treatment resources without having to travel in person.; Study phase: FDA approval. Outcome: ERT can delay progression, and the average life expectancy of male patients is about 50-60 years.
Frequently Asked Questions
What is Fabry disease?
Fabry disease is caused by mutations in the GLA gene that lead to a deficiency of alpha-galactosidase A, and glucosaccharide ceramide accumulates in the vascular endothelium and various tissues. It is an X-linked lysosomal storage disorder. Core dilemmas: ① Enzyme replacement therapy requires lifelong intravenous infusion;②ERT has limited effect on cardiac lesions;③ Some patients produce antibodies that affect efficacy;④ Cardiovascular, renal and cerebrovascular complications are the main cause of death.
What are the symptoms of Fabry disease?
GLA gene mutation,α-galactosidase A deficiency,Limb pain, hyposweating,Cardiovascular, renal and cerebrovascular disease
How is Fabry disease treated?
Agalsidase alfa/beta: Recombinant alpha-galactosidase A, given intravenously every 2 weeks, is the standard enzyme replacement treatment for Fabry disease.; Migalastat: Pharmacological companion, administered orally, indicated for patients with specific mutable types.; gene therapy: AAV vectors deliver normal GLA genes and are currently in clinical trials.
What is the prognosis for Fabry disease?
ERT delays progression, and the average life expectancy of male patients is approximately 50-60 years old